centres-of-excellence-clinical-research-centre-beacon-hospital-malaysia

临床研究中心

Beacon Hospital Clinical Research Center 成立于 2016 年。随后于 2020 年转变为我们的卓越中心 (COE) 之一,旨在使我们成为一家在临床研究方面具有诚信和道德行为的全球值得信赖的医院。

临床试验和研究是宝康医院临床研究中心循证研究方法的重要组成部分。在我们的患者、肿瘤学团队和临床研究团队的共同努力下,我们确实为许多临床试验做出了贡献,并在马来西亚推出了数量可观的肿瘤药物。根据 Clinical Research Malaysia(CRM)的官方报告,这也让我们自豪地成为 2021 年马来西亚在肿瘤学领域的顶级临床试验基地之一。

如果您有兴趣并想了解更多关于这些正在进行的试验,请致电 +603-7787 2830 联系我们,或者您可以发送电子邮件至 clinicalresearch@beaconhospital.com.my

为什么是我们

为了配合马来西亚政府使该国成为临床研究领域重要的全球参与者的长期重点,我们致力于寻找更好的方法来治疗癌症并帮助癌症患者。

除了我们所有的临床研究都获得马来西亚卫生部医学和研究伦理委员会的批准外,我们还遵守当地和国际 Good Clinical Practise (GCP) 标准,以维护试验患者的伦理利益。

正在进行的临床试验

迄今为止,我们的肿瘤科团队已参与多项临床试验,包括比较不同化疗的疗效;对抑制剂的抵抗力;鼻咽癌的表观遗传变化;以及治疗晚期或转移性胃食管连接部腺癌等。

临床试验列表

乳腺癌

No. Clinical Trial Status Clinical Trial Gov
1 TENOR
Phase II Study to assess the efficacy of Talazoparib in asian mEtastatic breast caNcer patients with a hOmologous Recombinant deficiency (HRD) signature (TENOR)
Active (Recruiting) NA
2 OPERA-01
A phase 3 randomized, open-label study of OP-1250 monotherapy vs SOC for the treatment of ER+, HER2- advanced or metastatic breast cancer following endocrine and CDK4/6 inhibitor therapy
Active (Recruiting) study of OP-1250 monotherapy vs SOC
3 EPIK-B3
CBYL719H12301 (EPIK B3) – A Phase III, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation.
Closed Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel
4 EPIK-B2
CBYL719G12301 (EPIK B2) – A two part, Phase III, multicenter, randomized (1:1), double-blind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with transtuzumab and pertuzumab as maintenance therapy in patients with HER2-positive advanced breast cancer with a PIK3CA mutation.
Closed Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Trastuzumab
5 lidERA
A phase III, randomized, open-label, multicenter study evaluating the efficacy and safety of adjuvant giredestrant compared with physician’s choice of adjuvant endocrine monotherapy in patients with estrogen receptor-positive, her2-negative early breast cancer
Closed Study Evaluating the Efficacy

肺癌

No Clinical Trial Status Clinical Trial Gov
1 ATORG001

A prospective, molecular profiling study of mutational genes in Asian patients with Non-Small Cell Lung Cancer. (Non-interventional study).

Active (Recruiting) Study of mutational genes in Asian patients
2 ATORG004

Plasma Molecular Profiling in ALK inhibitor resistant non-small cell lung cancer

Active (Recruiting) Plasma Molecular Profiling in ALK inhibitor resistant non-small cell lung cancer
3 PACIFIC-8

A Phase 3, Randomised, Double blind, Placebo controlled, Multicentre, International Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced (Stage III), Unresectable Non small Cell Lung Cancer Whose Disease has not Progressed Following Definitive Platinum based Concurrent Chemoradiation Therapy (PACIFIC-8)

Active (Recruiting) Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced
4 ADAURA-2

D516FC00001 – A Phase III, Double-blind, Randomized, Placebo-Controlled, International Study to assess the Efficacy and Safety of Adjuvant Osimertinib versus Placebo in Patients with EGFR mutation-positive, Stage IA2-IA3 Non-small Cell Lung Cancer, following Complete Tumor Resection

Active (Recruiting) Study to assess the Efficacy and Safety of Adjuvant Osimertinib
5 kontRASt-02

CJDQ443B12301 : A randomized, controlled, open label, phase III study evaluating the efficacy and safety of JDQ443 versus docetaxel in previously treated subjects with locally advanced or metastatic KRAS G12C mutant non-small cell lung cancer

Active (Recruiting) A randomized, controlled, open label, phase III study evaluating the efficacy and safety of JDQ443
6 MK3475-D46

Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50%

Active (Recruiting) Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan
7 Paloma-2

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

Active (Recruiting) Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors
8 BGB-LC-201

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

Active (Recruiting) Study of Tislelizumab in Combination With Investigational Agents
9 INSIGHT-2A

Phase II, two-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior osimertinib therapy

Closed Study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic non-small cell lung cancer (NSCLC)
10 LAURA

A Phase III, randomized, double-blind, placebo-controlled, multicenter, international study of osimertinib as maintenance therapy in patients with locally advanced, unresectable EGFR mutation-positive on-Small Cell Lung Cancer (Stage III) whose disease has not progressed following definitive platinum-based chemoradiation therapy.

Closed Study of osimertinib as maintenance therapy in patients with locally advanced
11 MARIPOSA

A Randomized Study of JNJ-61186372 and Lazertinib Combination Therapy Versus Single Agent Osimertinib or Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.

Closed Study of JNJ-61186372 and Lazertinib Combination Therapy Versus Single Agent Osimertinib or Lazertinib as First-Line Treatment
12 ATORG003

A single-arm, open-label, phase 2 study of Dacomitinib with or without dose titration for the first-line treatment of locally advanced or metastatic non-small cell lung cancer in subjects with an epidermal growth factor receptor (egfr) activation mutation

Closed Study of Dacomitinib with or without dose titration for the first-line treatment of locally advanced
13 ML41262

A Prospective, Multicentre, Genomic Profiling Study In Patients With Locally Advanced Or Metastatic Non-small Cell Lung Cancer (NSCLC) In Malaysia Using Foundation Medicine

Closed
14 INCMGA 0012-304

A Randomized, Double Blind, Phase 3 Study of Platinum-based Chemotherapy with or without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer Participants

Closed Study of Platinum-based Chemotherapy with or without INCMGA00012
15 PFIZER A7471067

Real-world utilization and outcomes with “study drug” first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer among Asian patients – A multi-center chart review

Closed Real-world utilization and outcomes with “study drug” first-line treatment
16 MK7684A-002

“A Phase II, multicenter, randomized study to compare the efficacy and safety of MK-7684A or MK-7684A plus Docetaxel versus Docetaxel monotherapy in the treatment of participants with metastatic non-small cell lung cancer with progressive disease after treatment with a platinum doublet chemotherapy and immunotherapy”

Closed Study to compare the efficacy and safety of MK-7684A or MK-7684A plus Docetaxel
17 MARIPOSA2

A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

Closed A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy

肝细胞癌

No Clinical Trial Status Clinical Trial Gov
1 MO42541

A phase III, open-label, randomized study of atezolizumab with lenvatinib or sorafenib versus lenvatinib or sorafenib alone in HCC previously treated with atezolizumab and bevacizumab

Closed Study of atezolizumab with lenvatinib or sorafenib

结直肠癌

No Clinical Trial Status Clinical Trial Gov
1 Origami-1

A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

On Hold Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy
2 MK4280A-007

A Phase 3 study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Standard of Care in Previously Treated Metastatic PD-L1 positive Colorectal Cancer

Closed Study of atezolizumab with lenvatinib or sorafenib
3 Krystal-10

A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy

Closed Study of MRTX849 in Combination with Cetuximab

实体肿瘤

 

No Clinical Trial Status Clinical Trial Gov
1 PRL3-Zumab

An Open Label, Multicenter, Safety and Efficacy Phase II/III Study of PRL3-Zumab in Solid Tumors Patients

Active (Recruiting) NA

血液学

No Clinical Trial Status Clinical Trial Gov
1 GCT3014-01

An Open-Label, Multicenter, Phase 1/2 Study of GEN3014 (HexaBody®-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies

Active (Recruiting) Study of GEN3014 (HexaBody®-CD38)
1 IMR Bortezomib

Genetic Variation Associated with Bortezomib Induced Peripheral Neuropathy in Adult Multiple Myeloma Patients (Investigator initiated study)

Active (Recruiting) NA

List Of Publications

除了肿瘤学临床试验,来自其他卓越中心的顾问也通过发表研究论文为临床专业做出了重大贡献。以下是我们的顾问发表的研究成果(摘要、研究论文、海报等):

Publication Title

No Publication Title Name of Consultant Type of Presentation
1 Healthcare Performance Measurement And Reporting System (HPMRS) For Cancer Care
2 Healthcare Performance Measurement And Reporting For Breast Cancer Services in Malaysia
3 Does A Picture Really Paint A Thousand Words? A Study On The Technical Qualities Of Online Aesthetic Oculofacial Clinical Photographs Dr Ong Chin Tuan (Consultant Ophthalmologist) Poster
4 Breast cancer survivorship in an Asian specialist centre from Malaysia: A retrospective analysis Dato Ibrahim
Dr Azura
Arkonam Balasubramaniam Manivannan (Consultant Oncologists)
Jessica Tan Jia Shin, Ph.D (Clinical Informatics Specialist)
Original Article
5 Presenting complaints of patients and palliative care referral patterns Dr Felicia Chang
Dr Azura
Jessica Tan Jia Shin, Ph.D (Clinical Informatics Specialist)
6 KASRP

Impact of a digital educational program on nurses’ knowledge and attitudes toward pain assessment and management in a Malaysian hospital.

Dr Koon Sim Lan
Jessica Tan Jia Shin, Ph.D (Clinical Informatics Specialist)
7 Retrospective Analysis of Clinical Outcomes of Stereotactic Body Radiation Therapy for Localized Prostate Cancer at an Asian Cancer Specialist Centre Jasmin Loh Pei Yuin,
Jessica Tan Jia Shin,
Chen Bao Jing,
Tho Lye Mun,
Manivanna Arkonam Balasubramaniam,
Dato Mohamed Ibrahim Wahid
Original Article
8 Topical nonsteroidal anti‐inflammatory drugs for management of osteoarthritis pain: A consensus recommendation Joon-Kiong Lee,
Azlina A.Abbas,
Tien-Eang Cheah,
Ruslan Nazaruddin Simanjuntak,
Sargunan Sockalingam,
Sharifah Roohi
Original Article

如果您有兴趣并想了解更多关于这些正在进行的试验,请通过+603-7787 2830 与我们联系,或者您可以给我们发邮件 clinicalresearch@beaconhospital.com.my.

Find Related Consultants

View More